Depomed (DEPO) Tops Q2 EPS by 27c; Boosts FY15 Outlook

Depomed (NASDAQ: DEPO) reported Q2 EPS of $0.27, $0.27 better than the analyst estimate of $0.00. Revenue for the quarter came in at $94.3 million versus the consensus estimate of $88.33 million.

Depomed sees FY2015 revenue of $320-340 million, versus prior guidance of $335-310 million. The company sees adjusted earnings of $40 - $50 million, from prior expectations of $16 - 28 million.

For earnings history and earnings-related data on Depomed (DEPO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS cuts KOSPI target by nearly 10% to reflect higher rates
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2